目的：观察康艾注射液对鼻咽癌患者外周血T细胞亚群的影响。方法：将60例行首次放疗的鼻咽癌患者采用随机数字表法随机分为治疗组和对照组各30例。对照组采用常规分割外照射治疗,放疗或放化疗期间给予常规药物对症治疗,以及营养支持,但...目的：观察康艾注射液对鼻咽癌患者外周血T细胞亚群的影响。方法：将60例行首次放疗的鼻咽癌患者采用随机数字表法随机分为治疗组和对照组各30例。对照组采用常规分割外照射治疗,放疗或放化疗期间给予常规药物对症治疗,以及营养支持,但不使用康艾注射液以及其他可能会影响免疫功能的中成药针剂（如参麦注射液等）。治疗组在对照组治疗基础上加用康艾注射液,从放疗第1天开始,采用康艾注射液40 m L加入50 g/L葡萄糖注射液或90 g/L生理盐水250-500 m L中,静脉滴注,1次/d,3-5次/周。两组均以30 d为1个疗程,治疗1个疗程后判定疗效。结果：治疗组治疗后CD3＋、CD4＋、CD8＋值较治疗前差别有统计学意义（P〈0.01）;且治疗组治疗后CD3＋、CD4＋、CD8＋、CD4＋/CD8＋值较对照组差别有统计学意义（P〈0.05）。结论：辅助静脉滴注康艾注射液能改善鼻咽癌患者的免疫功能,值得临床推广。展开更多
Objective： To investigate the effect and clinical significance of Xuebijing injection on peripheral T-lymphocyte subpopulations in patients with severe trauma. Methods： Thirty-three patients with severe trauma were...Objective： To investigate the effect and clinical significance of Xuebijing injection on peripheral T-lymphocyte subpopulations in patients with severe trauma. Methods： Thirty-three patients with severe trauma were randomly divided into a control group （n=16） and a treatment group （n=17）. The patients of two groups were all treated conventionally, and the only difference was that Xuebijing injection was given to patients of the treatment group. The CD4^＋ and CD8^＋ subpopulations of T-lymphocyte in the peripheral blood were detected respectively on admission, 3rd and 5th days after trauma by double antibody labeling and flow cytometry. Results： The CD4^＋ T-lymphocytes and CD4^＋/CD8^＋ ratio of peripheral blood in patients with severe trauma decreased markedly on the 3rd and 5th days after trauma. Furthermore, compared with control group, the peripheral CD4^＋ T-lymphocytes and CD4^＋/CD8^＋ ratio of treatment group renewed obviously on the 5th day after trauma, and showed statistical differences （P〈0.05）. Conelusion： In the treatment of patients with severe trauma, the early use of Xuebijing injection is effective in correcting disorder or suppression of T-lymphocyte subpopulations regulating network, and promoting a more balanced profile of immunologic function.展开更多
文摘目的：观察康艾注射液对鼻咽癌患者外周血T细胞亚群的影响。方法：将60例行首次放疗的鼻咽癌患者采用随机数字表法随机分为治疗组和对照组各30例。对照组采用常规分割外照射治疗,放疗或放化疗期间给予常规药物对症治疗,以及营养支持,但不使用康艾注射液以及其他可能会影响免疫功能的中成药针剂（如参麦注射液等）。治疗组在对照组治疗基础上加用康艾注射液,从放疗第1天开始,采用康艾注射液40 m L加入50 g/L葡萄糖注射液或90 g/L生理盐水250-500 m L中,静脉滴注,1次/d,3-5次/周。两组均以30 d为1个疗程,治疗1个疗程后判定疗效。结果：治疗组治疗后CD3＋、CD4＋、CD8＋值较治疗前差别有统计学意义（P〈0.01）;且治疗组治疗后CD3＋、CD4＋、CD8＋、CD4＋/CD8＋值较对照组差别有统计学意义（P〈0.05）。结论：辅助静脉滴注康艾注射液能改善鼻咽癌患者的免疫功能,值得临床推广。
基金This study-was supported by the Traditional Chinese Medical Science Foundation of Zhejiang Province （No. 2005C052）.
文摘Objective： To investigate the effect and clinical significance of Xuebijing injection on peripheral T-lymphocyte subpopulations in patients with severe trauma. Methods： Thirty-three patients with severe trauma were randomly divided into a control group （n=16） and a treatment group （n=17）. The patients of two groups were all treated conventionally, and the only difference was that Xuebijing injection was given to patients of the treatment group. The CD4^＋ and CD8^＋ subpopulations of T-lymphocyte in the peripheral blood were detected respectively on admission, 3rd and 5th days after trauma by double antibody labeling and flow cytometry. Results： The CD4^＋ T-lymphocytes and CD4^＋/CD8^＋ ratio of peripheral blood in patients with severe trauma decreased markedly on the 3rd and 5th days after trauma. Furthermore, compared with control group, the peripheral CD4^＋ T-lymphocytes and CD4^＋/CD8^＋ ratio of treatment group renewed obviously on the 5th day after trauma, and showed statistical differences （P〈0.05）. Conelusion： In the treatment of patients with severe trauma, the early use of Xuebijing injection is effective in correcting disorder or suppression of T-lymphocyte subpopulations regulating network, and promoting a more balanced profile of immunologic function.
